Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Amg 416
2. Amg-416
3. Etelcalcetide Hydrochloride
4. Kai-4169
5. Parsabiv
6. Velcalcetide
1. Velcalcetide
2. Parsabiv
3. 1262780-97-1
4. Kai-4169
5. Amg-416
6. Telcalcetide
7. 60me133fjb
8. Ono-5163
9. D-argininamide, N-acetyl-d-cysteinyl-d-alanyl-d-arginyl-d-arginyl-d-arginyl-d-alanyl-, Disulfide With L-cysteine
10. Etelcalcetide [usan:inn]
11. Unii-60me133fjb
12. Kai 4169
13. Amg416
14. Etelcalcetide [mi]
15. Etelcalcetide [inn]
16. Etelcalcetide (usan/inn)
17. Etelcalcetide [usan]
18. Etelcalcetide [who-dd]
19. Gtpl8375
20. Chembl3545184
21. Schembl21982605
22. Dtxsid70155132
23. Chebi:134700
24. Etelcalcetide [orange Book]
25. Hy-p1955
26. Akos037648615
27. Etelcalcetide Hydrochloride(amg-416)
28. Db12865
29. Bs-14875
30. Cs-0030931
31. J3.559.823e
32. D10676
33. D71178
34. Q21098973
35. N-acetyl-d-cysteinyl-d-alanyl-d-arginyl-d-arginyl-d-arginyl-d-alanyl-d-argininamide Disulfide With L-cysteine
36. S-(((s)-2-acetamido-3-(((r)-1-(((r)-1-(((r)-1-(((r)-1-(((r)-1-(((r)-1-amino-5-guanidino-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)-l-cysteine
Molecular Weight | 1048.3 g/mol |
---|---|
Molecular Formula | C38H73N21O10S2 |
XLogP3 | -10.7 |
Hydrogen Bond Donor Count | 18 |
Hydrogen Bond Acceptor Count | 17 |
Rotatable Bond Count | 36 |
Exact Mass | 1047.52906996 g/mol |
Monoisotopic Mass | 1047.52906996 g/mol |
Topological Polar Surface Area | 618 Ų |
Heavy Atom Count | 71 |
Formal Charge | 0 |
Complexity | 1910 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 1 | |
---|---|
Drug Name | PARSABIV |
Active Ingredient | ETELCALCETIDE |
Company | KAI PHARMS INC (Application Number: N208325. Patents: 8377880, 8999932, 9278995, 9701712, 9820938) |
Etelcalcetide is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.
Following a single intravenous bolus administration of etelcalcetide, PTH levels decreased within 30 minutes post dose. In the single-dose study, the extent and duration of the reduction in PTH increased with increasing dose. Reduction in PTH levels correlated with plasma etelcalcetide concentrations in hemodialysis patients. The reduction in PTH resulted in reductions in calcium and attenuation of post-dialytic phosphate elevation. The effect of reducing PTH levels was maintained throughout the 6-month dosing period when etelcalcetide was administered by intravenous bolus three times a week.
H05BX04
H05BX04
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
H - Systemic hormonal preparations, excl. sex hormones and insulins
H05 - Calcium homeostasis
H05B - Anti-parathyroid agents
H05BX - Other anti-parathyroid agents
H05BX04 - Etelcalcetide
Absorption
The pharmacokinetics of etelcalcetide is linear and does not change over time following single (5 to 60 mg) and multiple intravenous doses (2.5 to 20 mg) in chronic kidney disease patients with secondary hyperparathyroidism requiring hemodialysis. Etelcalcetide exhibited tri-exponential decay following intravenous administration. Based on population pharmacokinetic analysis, following three times a week intravenous dosing at the end of each 3- to 6-hour hemodialysis session in chronic kidney disease patients, etelcalcetide plasma levels reached steady state in 7-8 weeks after dosing with a predicted accumulation ratio of 3- to 4-fold
Route of Elimination
Etelcalcetide is cleared by renal excretion
Volume of Distribution
796 L
Clearance
7.66 L/hr
Etelcalcetide is not metabolized by CYP450 enzymes. Etelcalcetide is biotransformed in blood by reversible disulfide exchange with endogenous thiols to predominantly form conjugates with serum albumin. Following a single radiolabeled dose of etelcalcetide in chronic kidney disease patients with secondary hyperparathyroidism requiring hemodialysis, the plasma exposure of biotransformation products is approximately 5-fold higher than that of etelcalcetide and their concentration-time course parallels that of etelcalcetide.
3 to 4 days
Etelcalcetide is a calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR). Etelcalcetide binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : Yes
TE Code :
Brand Name : PARSABIV
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 2.5MG/0.5ML (2.5MG/0.5ML)
Approval Date : 2017-02-07
Application Number : 208325
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : PARSABIV
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 5MG/ML (5MG/ML)
Approval Date : 2017-02-07
Application Number : 208325
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : PARSABIV
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 10MG/2ML (5MG/ML)
Approval Date : 2017-02-07
Application Number : 208325
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Related Excipient Companies
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2034-06-27
US Patent Number : 9820938
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208325
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-06-27
Patent Expiration Date : 2030-07-29
US Patent Number : 8377880
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208325
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-07-29
Patent Expiration Date : 2034-06-27
US Patent Number : 11959486
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208325
Patent Use Code : U-2014
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-06-27
Patent Expiration Date : 2030-07-29
US Patent Number : 8377880
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208325
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-07-29
Patent Expiration Date : 2034-06-27
US Patent Number : 11162500
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208325
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-06-27
Patent Expiration Date : 2034-06-27
US Patent Number : 11959486
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208325
Patent Use Code : U-2014
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-06-27
Patent Expiration Date : 2031-02-07
US Patent Number : 8999932
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208325
Patent Use Code : U-2014
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-02-07
Patent Expiration Date : 2030-07-29
US Patent Number : 8377880
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208325
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-07-29
Patent Expiration Date : 2030-07-29
US Patent Number : 9701712
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208325
Patent Use Code : U-2014
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-07-29
Patent Expiration Date : 2034-06-27
US Patent Number : 9820938
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208325
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-06-27
ABOUT THIS PAGE
A Etelcalcetide Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Etelcalcetide Hydrochloride, including repackagers and relabelers. The FDA regulates Etelcalcetide Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Etelcalcetide Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Etelcalcetide Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Etelcalcetide Hydrochloride supplier is an individual or a company that provides Etelcalcetide Hydrochloride active pharmaceutical ingredient (API) or Etelcalcetide Hydrochloride finished formulations upon request. The Etelcalcetide Hydrochloride suppliers may include Etelcalcetide Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Etelcalcetide Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Etelcalcetide Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Etelcalcetide Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Etelcalcetide Hydrochloride DMFs exist exist since differing nations have different regulations, such as Etelcalcetide Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Etelcalcetide Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Etelcalcetide Hydrochloride USDMF includes data on Etelcalcetide Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Etelcalcetide Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Etelcalcetide Hydrochloride suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Etelcalcetide Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Etelcalcetide Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Etelcalcetide Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Etelcalcetide Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Etelcalcetide Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Etelcalcetide Hydrochloride suppliers with NDC on PharmaCompass.
Etelcalcetide Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Etelcalcetide Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Etelcalcetide Hydrochloride GMP manufacturer or Etelcalcetide Hydrochloride GMP API supplier for your needs.
A Etelcalcetide Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Etelcalcetide Hydrochloride's compliance with Etelcalcetide Hydrochloride specifications and serves as a tool for batch-level quality control.
Etelcalcetide Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Etelcalcetide Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Etelcalcetide Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Etelcalcetide Hydrochloride EP), Etelcalcetide Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Etelcalcetide Hydrochloride USP).
LOOKING FOR A SUPPLIER?